CTOs on the Move

Homology Medicines

www.homologymedicines.com

 
Homology is based on groundbreaking science that harnesses the naturally occurring process of homologous recombination. This non-nuclease-based approach offers clear advantages in its precision, efficiency and on-target in vivo editing of genetic mutations. Homology obtained an exclusive worldwide license to this technology platform, which is based on the pioneering research of Saswati Chatterjee, Ph.D., Professor of Virology at the Beckman Research Institute at the City of Hope in California, member of the Recombinant DNA Advisory Committee (RAC) to the Office of the Director, National Institutes of Health (NIH) and former charter member of the Therapeutic Approaches to Genetic Diseases Study ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Homology Medicines raised $43.5M on 05/02/2016
Homology Medicines raised $83.5M on 08/01/2017

Similar Companies

Novome Biotechnologies

Novome Biotechnologies is engineering bacteria from the human gut to treat diseases. Based on pioneering technology developed at Stanford University, we bring together experts in the fields of synthetic biology and the microbiome to build novel cell-based therapies.

BioVision

BioVision is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gel-Del

Gel-Del is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Daiichi Sankyo

Daiichi Sankyo, Inc. headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Daiichi Sankyo, Co., Ltd. and a member of the Daiichi Sankyo Group. Global clinical development and regulatory activities are headquartered at Daiichi Sankyo Pharma Development in Edison, New Jersey. Our team of more than 1,400 U.S. employees is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs. We currently market therapies in hypertension, thrombotic disorders, stroke risk reduction, dyslipidemia, diabetes, acute coronary syndrome, opioid-induced constipation and metastatic melanoma. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group’s 2025 Vision to become a “Global Pharma Innovator with a Competitive Advantage in Oncology,” Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases. IMPORTANT NOTE: We are very pleased to announce the location of Daiichi Sankyo, Inc.’s new US headquarters where our Parsippany- and Edison-based teams will be co-located in a combined site in early to mid-2017. Our new headquarters will be in Basking Ridge, New Jersey at 211 Mt. Airy Road.

Labo America Inc

Labo America Inc is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.